Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

Study Overview
=================
Brief Summary
-----------------
This study investigated whether a calibrated reduction in antiretroviral drug pressures could stabilize the evolution and the pathogenic potential of resistant HIV viruses.

Detailed Description
-----------------
In patients with HIV multidrug resistance, maintaining a failing full-dose HAART regimen usually results in significant drug toxicity and in continued accumulation of resistance mutations that can preclude future therapeutic options. In contrast, treatment interruption provokes the reemergence of wild-type virus with full replicative and pathogenic capacity. The researchers investigated whether a calibrated reduction in drug pressure could stabilize the evolution and the pathogenic potential of resistant virus. A prospective pilot study was conducted in patients receiving protease inhibitor-based HAART with a resistance genotype predicting less than two active drugs according to the 2002 ANRS algorithm, CD4 counts over or equal to 100/mm3 and plasma HIV RNA below or equal to 5 log/ml. The treatment was low-dose IDV/RTV (200/100 BID) and 3TC 150mg BID. IDV doses were adjusted at week 4 to ensure a Cmin of 250+/-100ng/ml, which, based on a panel of multi-PI resistant viruses, was calculated to yield an inhibitory quotient (Cmin/IC50) of 0.50. Primary end-points were over 25% decrease in CD4 counts (immunological failure-IF), or over 0.7 log increase in plasma HIV RNA (virological failure-VF) at two consecutive monthly visits during the 24-week study. Inclusions were to stop when the total number of failures (VF+IF) reached 7

Official Title
-----------------
Efficacy and Tolerability of an Antiretroviral bi-Therapy in HIV-1 Infected Patients With Multidrug Resistant HIV ANRS 109 Vista Trial.

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Indinavir
* Drug: Lamivudine
* Drug: Ritonavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV-1 infection confirmed by Western Blot Karnofsky score over or equal to 70 CD4 over or equal to 200/mm3 Plasma viral RNA over or equal to 10 000 copies/ml and below 100 000 copies/ml. Stability of plasma viral load and CD4-during the last 3 months failure of two antiretroviral regimens with 2 PI and one NNRTI New efficacy drug on genotype not available Treatment on hand with 3 antiretroviral drugs with one PI since 3 months. Written inform consent Pregnancy Exclusion Criteria: Hemoglobin below 8g/dL Neutrophils below 750/mm3 ASAT, ALAT over 5N Hepatic insufficiency (prothrombin below 50%) Acute opportunistic infection Immunotherapy Treatment with active antiretroviral regimen Treatment with enzyme inductor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Indinavir|nan|
|Drug: Lamivudine|nan|
|Drug: Ritonavir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease over 25% in CD4 counts (immunological failure-IF), or increase over 0.7 log in plasma HIV RNA (virological failure-VF) at two consecutive monthly visits during the 24-week study |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of an HIV-1-related AIDS defining event |  |  | 
| Death |  |  | 
| Change in CD4 cell count between baseline and week 24 |  |  | 
| Change in plasma HIV-RNA level between baseline and week 4, week 8, week 12 and week 24 |  |  | 
| Change in genotypic and phenotypic resistance between baseline and week 2 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment Failure, HIV infections